Presented by: William J. Polvino, MD, Bridge Medicines
About Episode 6
Drug development is a race – time matters. In episode 6, Bill expands on this idea and shares how a collaboration between academia and private sources can accelerate time to market.
About Bill Polvino
Bill is CEO of Bridge Medicines, a company established in 2016 to further the development of drugs nurtured by the Tri-Institutional Therapeutics Discovery Institute. The Tri-I TDI, as it’s known, is a nonprofit that brings together Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, The Rockefeller University and Takeda Pharmaceutical Company Ltd. to support investigations into promising therapeutics.
Complete the form to the right for access to episode 6 of the Charles River Innovator's Series.